Europe Medical Cannabis Market is expected to grow with a CAGR of 29.5% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.
Access Full Report @ https://www.databridgemarketresearch.com/reports/europe-medical-cannabis-market
The Europe medical cannabis market is a highly fragmented market, which includes huge number of key players. The market has witnessed increasing strategic developments owing to favourable market scenario.
The major players dealing in Europe Medical cannabis market are introducing strong range of products provider along with launching new products and adopting strategic initiatives such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.
Tilray is the dominating player in Europe Medical cannabis market. The other key players existing in the market are Jazz Pharmaceuticals, Inc., Aurora Cannabis Inc. are Medipharm Labs, Althea Company Pty Ltd, PharmaHemp, Elixinol Global Limited, CANOPY GROWTH CORPORATION, ECOGEN BIOSCIENCES, Little Green Pharma, GRASS & CO., CANNARAY, Sanity Group GmbH., VIVO Cannabis Inc., HEXO Corp., and Marrican Inc, among others.
Tilray is headquartered in the New York, U.S. and was founded in the year 2013. The company focuses on cannabis research, cultivation, processing, and distribution. The various business segments of the company include cannabis business, distribution business, beverage alcohol business, wellness business out of which cannabis business is the market-focused business category.
The company has a presence across North America, Europe, South America, Asia-Pacific and Middle East and Africa. The company has various subsidiaries that are Tilray Canada (Canada), Tilray Europe (Europe), Tirlary Australia & New Zealand (Australia), Manitoba Harvest (USA), High Park Company (Canada), among others.
Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc. is headquartered in Dublin, Ireland and was founded in the year 2003. The company is focused on developing life-changing medicines for people with serious diseases who often have limited or no options. The company operates in various product segments such as neuroscience therapeutic area and oncology therapeutic area in which neuroscience therapeutic area is a market-focused category.
The company has a presence across North America, Europe. In addition, the company has various subsidiaries that are, GW Pharmaceuticals (U.K.), Celator Pharmaceuticals Inc. (The U.S.), Gentium SpA (Italy), Cavion LLC (U.K.), GW Research Ltd (U.K.), among others.
Aurora Cannabis Inc.
Aurora Cannabis Inc. is headquartered in Alberta, Canada and was founded in the year 2014. The company focuses on providing a wide range of premium quality cannabis and hemp products and services, develops innovative technologies, promotes cannabis consumer health and wellness. The various product categories of the company include dried flower, cannabis oil, capsules, edibles, vapes, concentrates, topicals, accessories in which dried flower, cannabis oil, capsules, edibles, vapes, topicals are the market focused category.
The company has a presence across North America, Europe, South America, Asia-Pacific, Middle East and Africa. In addition, the company also generates its revenue from various subsidiaries including Aurora Deutschland GmbH (Germany), Cannimed (Canada), Reliva, LLC (U.S.), Aurora Europe GmbH (Germany), Pedanios GmbH (Germany), among others.
North America Medical Cannabis Market – Industry Trends and Forecast to 2028
Asia-Pacific Medical Cannabis Market – Industry Trends and Forecast to 2028
Middle East and Africa Medical Cannabis Market – Industry Trends and Forecast to 2028
Thailand Medical Cannabis Market – Industry Trends and Forecast to 2028
Global Medical Cannabis Market - Industry Trends and Forecast to 2028
Europe Medical cannabis Market – Industry Trends and Forecast to 2029